Minimally invasive heart bypass surgery with a blood-thinner medication
Part of Heart & circulation clinical trials.
This trial tests whether a blood-thinner drug called cangrelor helps patients who are having a special type of bypass surgery that uses a small incision instead of opening the whole chest. The surgery connects a healthy artery from your chest wall directly to a blocked heart vessel to restore blood flow.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You are scheduled for minimally invasive bypass surgery (MIDCAB) connecting your chest artery to your heart's left front vessel
- You have not had a recent stroke or bleed in your brain
- You do not have a known bleeding disorder or severe kidney or liver disease
- You are not pregnant or breastfeeding
- You are not having a stent procedure (PCI) at the same time as your bypass surgery
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new artificial blood vessel for heart bypass surgery. If you need a bypass and meet the health requirements, you may be able to receive this experimental graft.
This study follows patients who had a first-time heart bypass operation (CABG) to see how a blood-thinning medicine called ticagrelor affects their recovery and long-term health. It may help doctors understand the best way to prevent complications after surgery.
This trial looks at whether a “drug-coated balloon” used during a heart procedure (PCI) is safer or better for people who are at higher risk of bleeding while on blood thinners. It may help reduce complications around the time of the procedure in people like you.
This trial compares a less invasive robot-assisted heart bypass plus stenting against standard heart bypass surgery. It is for people with multiple blocked heart arteries who have extra risk factors that make regular surgery more dangerous.
This Phase 3 trial compares two strategies to prevent blood clots after heart bypass surgery: aspirin alone versus aspirin plus ticagrelor. It aims to see which approach works better and is safer for people whose bypass does not fully restore blood flow.
This trial compares two types of heart bypass surgery for people with blockages in three main heart arteries. It tests a hybrid approach that combines a small incision bypass with a stent, versus a standard off-pump bypass. This may mean less recovery time for some patients.
Hear when a new Coronary artery disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.